DE69126486D1 - Induzierung eines schutzes gegen virale infektionen - Google Patents

Induzierung eines schutzes gegen virale infektionen

Info

Publication number
DE69126486D1
DE69126486D1 DE69126486T DE69126486T DE69126486D1 DE 69126486 D1 DE69126486 D1 DE 69126486D1 DE 69126486 T DE69126486 T DE 69126486T DE 69126486 T DE69126486 T DE 69126486T DE 69126486 D1 DE69126486 D1 DE 69126486D1
Authority
DE
Germany
Prior art keywords
virus
induction
antibodies
protection against
viral infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69126486T
Other languages
English (en)
Other versions
DE69126486T2 (de
Inventor
Marc Girard
Marie-Paule Kieny
Claude Leclerc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Application granted granted Critical
Publication of DE69126486D1 publication Critical patent/DE69126486D1/de
Publication of DE69126486T2 publication Critical patent/DE69126486T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69126486T 1990-03-19 1991-03-16 Induzierung eines schutzes gegen virale infektionen Expired - Fee Related DE69126486T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49474990A 1990-03-19 1990-03-19
PCT/EP1991/000509 WO1991014449A1 (en) 1990-03-19 1991-03-16 Induction of protection against viral infection

Publications (2)

Publication Number Publication Date
DE69126486D1 true DE69126486D1 (de) 1997-07-17
DE69126486T2 DE69126486T2 (de) 1998-01-15

Family

ID=23965805

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69126486T Expired - Fee Related DE69126486T2 (de) 1990-03-19 1991-03-16 Induzierung eines schutzes gegen virale infektionen

Country Status (10)

Country Link
EP (2) EP0742229A3 (de)
JP (2) JPH03271233A (de)
AT (1) ATE154244T1 (de)
AU (3) AU651816B2 (de)
CA (1) CA2057040A1 (de)
DE (1) DE69126486T2 (de)
DK (1) DK0472706T3 (de)
ES (1) ES2104695T3 (de)
GR (1) GR3024670T3 (de)
WO (1) WO1991014449A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976541A (en) * 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US5876724A (en) * 1990-03-19 1999-03-02 Institut Pasteur Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
US6139843A (en) * 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
DE69233271T2 (de) * 1991-04-02 2004-09-09 Albert Einstein College Of Medicine Of Yeshiva University Therapeutischer- und präventivimpfstoff gegen hiv
JPH07501052A (ja) * 1991-10-28 1995-02-02 インスティチュート・パスツール ウイルスエンベロープタンパク質と糖タンパク質の中和エピトープに相当するペプチドとの間の相乗作用によるウイルス感染に対する防御の誘発
FR2692898B1 (fr) * 1992-06-30 1995-06-02 Centre Nat Rech Scient Procédé d'obtention de protéines membranaires, et utilisation de ces protéines dans un but de diagnostic ou de vaccination.
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2054616T3 (es) * 1985-12-17 1994-08-16 Akzo Nv Reactivo inmunoquimico.
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
ATE128716T1 (de) * 1987-11-24 1995-10-15 Abbott Lab Hiv-peptide und methoden für den nachweis von hiv.
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
FR2650954B1 (fr) * 1989-08-18 1992-02-28 Pasteur Institut Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida

Also Published As

Publication number Publication date
WO1991014449A1 (en) 1991-10-03
EP0742229A3 (de) 1998-06-03
EP0472706A1 (de) 1992-03-04
ATE154244T1 (de) 1997-06-15
EP0472706B1 (de) 1997-06-11
EP0742229A2 (de) 1996-11-13
JPH04506220A (ja) 1992-10-29
AU7196098A (en) 1998-08-13
GR3024670T3 (en) 1997-12-31
AU651816B2 (en) 1994-08-04
CA2057040A1 (en) 1991-09-20
DE69126486T2 (de) 1998-01-15
ES2104695T3 (es) 1997-10-16
AU7498991A (en) 1991-10-21
AU6461594A (en) 1994-09-08
DK0472706T3 (da) 1997-12-29
JPH03271233A (ja) 1991-12-03

Similar Documents

Publication Publication Date Title
EP0090581A3 (de) Kleine, für Maul- und Klauenseuche spezifische Peptide
ES2156199T3 (es) Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.
ATE430200T1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
ATE404220T1 (de) Rekombinierte pockenvirus-tollwut zusammensetzung und kombinierte zusammensetzungen und deren verwendung
DE69111801D1 (de) Vakzin gegen hepatitis b.
CA2091263A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
DE69322872D1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
ATE310014T1 (de) Hepatitis b-impfstoff
DE69126486D1 (de) Induzierung eines schutzes gegen virale infektionen
KR910000179A (ko) Aids용 결합체 면역원
WO2002057314A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
KR920004422A (ko) Hiv의 주요 중화 결정인자
DE69626642T2 (de) Cetp zur erhöhung des hdl-cholesterol-gehalts
DK0714307T3 (da) Vaccinesammensætninger
DK0439601T3 (da) Præparat indeholdende en B-epitop fra kappe- glycoproteinet fra et retrovirus og en T-epitop fra et protein, der er forskelligt fra dette retrovirus
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
SE9600436D0 (sv) Vaccine against hantavirus
CA2079230A1 (en) Bcrf1 antagonists for treating epstein-barr virus infections
DE69010897T2 (de) Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin.
RU93004854A (ru) Пептиды для вакцинации и индукции нейтрализующих антител против вируса иммунодефицита человека
KR970074790A (ko) 합성 펩티드를 함유하는 녹농균 백신 및 이것으로부터 생산된 치료제
CA2143187A1 (en) Anti-feline immunodeficiency virus (fiv) vaccines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee